BIOVIE INC (BIVI) Stock Price, Quote, News and Overview
NASDAQ:BIVI - Nasdaq - US09074F4054 - Common Stock - Currency: USD
BIVI Quote, Performance and Key Statistics
1.48
-0.15 (-9.2%)
The current stock price of BIVI is 1.48 USD. In the past month the price decreased by -23.71%. In the past year, price decreased by -87.46%.
BIVI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BIVI
Company Profile
BioVie Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Carson City, Nevada and currently employs 14 full-time employees. The company went IPO on 2014-01-14. BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Company Info
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404 US
CEO: Cuong Do
Employees: 14
Company Website: https://www.bioviepharma.com/
Investor Relations: https://bioviepharma.com/investors/
Phone: 17758883162
BIOVIE INC / BIVI FAQ
What is the stock price of BIOVIE INC today?
The current stock price of BIVI is 1.48 USD. The price decreased by -9.2% in the last trading session.
What is the ticker symbol for BIOVIE INC stock?
The exchange symbol of BIOVIE INC is BIVI and it is listed on the Nasdaq exchange.
On which exchange is BIVI stock listed?
BIVI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOVIE INC stock?
7 analysts have analysed BIVI and the average price target is 5.1 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 1.48. Check the BIOVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOVIE INC worth?
BIOVIE INC (BIVI) has a market capitalization of 27.31M USD. This makes BIVI a Nano Cap stock.
How many employees does BIOVIE INC have?
BIOVIE INC (BIVI) currently has 14 employees.
What are the support and resistance levels for BIOVIE INC (BIVI) stock?
BIOVIE INC (BIVI) has a resistance level at 1.73. Check the full technical report for a detailed analysis of BIVI support and resistance levels.
Should I buy BIOVIE INC (BIVI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIVI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIVI, evaluating the profitability, health, valuation and growth aspects
- BIOVIE INC (BIVI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOVIE INC (BIVI) Sales and EPS estimates to see what analysts future expectations are.
- BIOVIE INC (BIVI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOVIE INC (BIVI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOVIE INC (BIVI) Stock Chart to make your own analysis
- BIOVIE INC (BIVI) Latest news and press-releases to stay up to date.
Does BIOVIE INC (BIVI) stock pay dividends?
BIVI does not pay a dividend.
When does BIOVIE INC (BIVI) report earnings?
BIOVIE INC (BIVI) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of BIOVIE INC (BIVI)?
BIOVIE INC (BIVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.6).
What is the Short Interest ratio of BIOVIE INC (BIVI) stock?
The outstanding short interest for BIOVIE INC (BIVI) is 9.22% of its float. Check the ownership tab for more information on the BIVI short interest.
BIVI Technical Analysis
BIVI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIVI. BIVI has a great financial health rating, but its profitability evaluates not so good.
BIVI Financial Highlights
Over the last trailing twelve months BIVI reported a non-GAAP Earnings per Share(EPS) of -15.6. The EPS decreased by -24.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -99.36% | ||
| ROE | -106.72% | ||
| Debt/Equity | 0 |
BIVI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BIVI. The Buy consensus is the average rating of analysts ratings from 7 analysts.